Merrimack Pharmaceuticals, Inc. (MACK) News

Merrimack Pharmaceuticals, Inc. (MACK): $5.94

0.03 (+0.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MACK to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

Filter MACK News Items

MACK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest MACK News From Around the Web

Below are the latest news stories about Merrimack Pharmaceuticals Inc that investors may wish to consider to help them evaluate MACK as an investment opportunity.

Insider Buying: The Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Co-Founder & Independent Director Just Bought 63% More Shares

Even if it's not a huge purchase, we think it was good to see that Ulrik Nielsen, the Co-Founder & Independent Director...

Yahoo | January 27, 2022

Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | December 6, 2021

Merrimack Reports Third Quarter 2021 Financial Results

CAMBRIDGE, Mass., November 04, 2021--Merrimack Pharmaceuticals Reports Third Quarter 2021 Financial Results

Yahoo | November 4, 2021

A Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insider increased their holdings by 43% last year

Looking at Merrimack Pharmaceuticals, Inc.'s ( NASDAQ:MACK ) insider transactions over the last year, we can see that...

Yahoo | September 6, 2021

Merrimack Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass., August 05, 2021--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) ("Merrimack" or the "Company") today announced its second quarter 2021 financial results for the period ended June 30, 2021.

Yahoo | August 5, 2021

Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | June 8, 2021

Elevation Oncology Files for $100M IPO

Elevation Oncology has filed to raise $100 million in an IPO. See SEC prospectus here. Proceeds will be used to support the development of seribantumab that failed multiple trials at Merrimack Pharmaceuticals Inc (NASDAQ: MACK) before being picked up by Elevation and repositioned as a treatment for solid tumors harboring an NRG1 fusion. The anti-HER3 antibody failed multiple mid-phase trials, causing Sanofi SA (NASDAQ: SNY) to return the rights to the drug and ultimately leading to Merrimack off

Yahoo | June 7, 2021

180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors

MENLO PARK, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its Board of Directors (“Board”) effective June 15, 2021. Russell Ray was formerly Managing Director and Co-Head of Global Health Care at Credit Suisse First Boston Corporation where he led a 50-person team with offices in Baltimore, Chicago, London, New York and San Francisco focused on providing corporate finance and M&A advisory services to private and public companies in the biotechnology, health care services and health ...

Yahoo | May 28, 2021

Merrimack Reports Full Year 2020 Financial Results

Merrimack Reports Full Year 2020 Financial Results

Yahoo | March 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.691 seconds.